Stockscreener 앱 받기
112.13
1.59%
-1.462
전일 마감가:
$113.59
열려 있는:
$113.25
하루 거래량:
1.03M
Relative Volume:
0.12
시가총액:
$195.07B
수익:
$44.33B
순이익/손실:
$6.48B
주가수익비율:
30.28
EPS:
3.7033
순현금흐름:
$6.92B
1주 성능:
+2.48%
1개월 성능:
-10.32%
6개월 성능:
-14.68%
1년 성능:
-14.34%
1일 변동 폭
$111.52
$113.76
1주일 범위
$108.95
$113.76
52주 변동 폭
$105.27
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
112.18 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
368.55 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.25 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
73.41 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 46.04B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Labs: The healthcare dividend stock I'd happily hold forever - MSN
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever - AOL.com
Illinois Municipal Retirement Fund Has $22.46 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Cibc World Market Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Caisse Des Depots ET Consignations Buys 9,374 Shares of Abbott Laboratories $ABT - MarketBeat
‘Time to Buy,’ Says Options Trader Following Abbott’s (ABT) Earnings Implosion - TipRanks
Rhumbline Advisers Sells 57,100 Shares of Abbott Laboratories $ABT - MarketBeat
Jensen Investment Management Inc. Has $322.72 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Drug of Abuse Testing Market Is Going to Boom |• Abbott - openPR.com
US Says Abbott Lied, Must Repay Funds Spent On Formula - Law360
Exact Sciences Faces Shareholder Lawsuits Over Abbott Merger - TipRanks
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang - Bez Kabli
Abbott Laboratories price tries to correct main downward trendForecast today10-02-2026 - Economies.com
After a 15% Drop, Is Abbott Stock Set Up for a Comeback in 2026? - TIKR.com
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
Wealthfront Advisers LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat
Johnson Investment Counsel Inc. Has $130.71 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott details Volt, TactiFlex data; Pulse Biosciences’ results shine - MedTech Dive
Candriam S.C.A. Boosts Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by ProShare Advisors LLC - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After New AFib Catheter And Pulsed Field Ablation Data - simplywall.st
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Insider Stock Buying Reaches US$3.10m On Abbott Laboratories - Yahoo Finance
Abbott Laboratories $ABT Stake Lessened by Twin Capital Management Inc. - MarketBeat
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott Laboratories (NYSE:ABT) Director Daniel Starks Purchases 10,000 Shares - MarketBeat
William Blair Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com Nigeria
Abbott Labs director Starks buys shares worth $1.08 million - Investing.com
Catheter trials show Abbott devices cut AFib episodes for most patients - Stock Titan
Aurdan Capital Management LLC Lowers Stake in Abbott Laboratories $ABT - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Lowers Position in Abbott Laboratories $ABT - MarketBeat
UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News
BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
Bessemer Group Inc. Purchases 10,684 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Homestead Advisers Corp - MarketBeat
Abbott Laboratories $ABT Shares Bought by Savant Capital LLC - MarketBeat
US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.22%
0.07%
자본화:
|
볼륨(24시간):